Saturday 17 October 2026
Export NCEL’s income statement to Excel — free account
NewcelX Ltd.
NCEL Healthcare Biotechnology
Insiders bought in the last twelve months.
2.50
0.35
−12.28%
Follow NCEL
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.09 | 2.77 | 0.76 | 0.40 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 3.10% | 4.04% | |
Debt/Equity |
0.00 | 0.00 | 0.05 | 0.06 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.18) | 0.00 | (0.15) | 0.00 | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.71 | 0.84 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(4.27) | (2.07) | (2.77) | (2.87) | |
Working Capital |
(8.12) | 2.58 | (1.01) | (2.20) | |
Capital Expenditures |
0.00 | — | (0.01) | — | |
Net Current Asset Value |
(8.12) | 2.58 | (1.01) | (2.20) | |
| Other line items | |||||
Quick Ratio |
0.07 | 2.11 | 0.52 | 0.19 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | — | 0.00 | — | |
Average Payables |
1.44 | 2.07 | 3.40 | 3.09 | |
Average Assets |
5.09 | 3.30 | 6.65 | 5.45 | |
Average Common Equity |
(0.11) | (0.72) | (0.79) | (1.61) | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates